SCHEMBL18975170

SCHEMBL18975170

Cc1sc(N(CCC2CCCCC2)Cc2ccc(Cl)cc2)nc1C(=O)NS(C)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMKLR1 Q99788 3/20 0.42
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
SCN9A Q15858 4/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
CNR2 P34972 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAPT P10636 1/20 0.34
CXCR3 P49682 1/20 0.34
OGFRL1 Q5TC84 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18975177 0.92 CMKLR1 (0.43) CMKLR1GAASMN1; SMN2ALDH1A1HPGD
SCHEMBL18975171 0.91 CMKLR1 (0.43) CMKLR1GAASMN1; SMN2ALDH1A1HPGD
SCHEMBL18975167 0.91 GAA (0.37) CMKLR1GAASMN1; SMN2ALDH1A1HPGD
SCHEMBL18974645 0.91 LPAR1 (0.40) CMKLR1SMN1; SMN2SCN9AALDH1A1MEN1
SCHEMBL18975162 0.90 LPAR1 (0.40) CMKLR1SMN1; SMN2SCN9AALDH1A1MEN1
SCHEMBL18975179 0.87 CXCR3 (0.39) SCN9AALDH1A1KDM4ECXCR3
SCHEMBL18975157 0.86 LPAR1 (0.41) CMKLR1THRBLMNARXFP1MAPT
SCHEMBL18974929 0.86 CMKLR1 (0.45) CMKLR1GAASMN1; SMN2SCN9AALDH1A1
SCHEMBL22293306 0.85 SMN1; SMN2 (0.38) CMKLR1GAASMN1; SMN2ALDH1A1HPGD
SCHEMBL18975107 0.85 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3388425-B1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LTD (JP) 2020-08-05 EP disclosed
EP-3388425-B1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LTD (JP) 2020-08-05 EP disclosed
US-10689354-B2 Aminoazole derivative TEIJIN PHARMA LIMITED (JP) 2020-06-23 US disclosed
US-20190031628-A1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2019-01-31 US disclosed
EP-3388425-A1 AMINOAZOLE DERIVATIVE Teijin Pharma Limited (JP) 2018-10-17 EP disclosed
WO-2017099237-A1 AMINOAZOLE DERIVATIVE 帝人ファーマ株式会社 2017-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689354-B2 Aminoazole derivative AR, NR3C2, NR5A1 CMKLR1 194/4885GAA 4853/4885SMN1; SMN2 3517/4885
US-20190031628-A1 AMINOAZOLE DERIVATIVE AR, NR3C2, NR5A1 CMKLR1 194/4885GAA 4853/4885SMN1; SMN2 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.